March 18 - 19, 2021
Online
Why to participate at ADIT update:
-
Intriguing topics: COVID-19 and diabetes, New insights into the management of diabetes by lifestyle interventions, Pharmacotherapy updates.
-
The panel of globally recognized experts and researchers.
-
Program focused on translating research to clinical practice.
-
Exchange opinions and resolve dilemmas with peers and panelists through Q&A and panel discussion.
-
We applied for CME accreditation with UEMS EACCME.
We are inviting you to join colleagues from multiple countries and register for ADIT2021-Update. During these hard and challenging times, continuous medical education is more important than ever. At the same time, live CME meetings are affected by travel and gathering limitations.
Because of the unpredictable circumstances of setting up the next live ADIT conference, we decided to deliver these two-day programs online on March 18-19, 2021, to provide much-needed CME update to healthcare professionals and maintain the ADIT conference tradition.
Preliminary Program
THURSDAY, MARCH 18, 2021 | 16.30 pm – 19.30 pm (CET)
New insights into management of diabetes by lifestyle interventions |
Panelists: Matt Campbell, Panu Luukkonen, Aila Rissanen, Roy Taylor, Hannele Yki-Järvinen
Type 2 diabetes in the real world: From understanding aetiology to practical treatment | Roy Taylor, UK
Metabolic effects of a ketogenic diet | Panu Luukkonen, USA
Binge eating disorders (with case presentation) | Aila Rissanen, Finland
How to personalise exercise recommendations | Matt Campbell, UK
How effective is lifestyle management in advanced NAFLD | Hannele Yki-Järvinen, Finland
FRIDAY, MARCH 19, 2021 /16.30 pm – 19.30 pm (CET)
Pharmacotherapy; COVID-19 and diabetes |
Panelists: Geremia Bolli, Filip Krag Knop, Juris Meier, Dario Rahelic, Guntram Schernthaner
GIP physiology - is there therapeutic potential? | Filip K. Knop, Denmark
New aspects of incretin mimetics | Juris Meier, Germany
Pro´s of a once a week Insulin- are there any con´s | Geremia Bolli, Italy
Lessons from recent trials of SGLT-2 inhibitors | Guntram Schernthaner, Austria
Management of patients with diabetes and obesity in the COVID-19 era | Dario Rahelic, Croatia (TBC)
Dario Rahelic
Croatia
Aila Rissanen
Finland
Guntram Schernthaner
Austria
Roy Taylor
United Kingdom